Humira

(Adalimumab)

ApprovedMonoclonal antibody

Adalimumab is used to treat inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease by reducing the immune system's inflammatory response. It helps relieve pain, swelling, and other symptoms caused by these autoimmune diseases.[2] Humira is currently approved and in use across 59 indications[4].[1]

Humira is one of 934 monoclonal antibody programs targeting Pyoderma Gangrenosum. It is currently in Approved.

Indications

412

Total Trials

Active Trials

933

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Pyoderma GangrenosumActive, not recruiting

Relapsing PolychondritisActive, not recruiting

Choroidal NeovascularizationActive, not recruiting

PanuveitisUnknown

PyodermaActive, not recruiting

Anal FistulaActive, not recruiting

ArthritisUnknown

Rheumatic DiseaseRecruiting

Anterior UveitisActive, not recruiting

Psoriasis VulgarisUnknown

Pyoderma GangrenosumPhase 2

Active, not recruiting

Relapsing PolychondritisPhase 2

Active, not recruiting

Choroidal NeovascularizationPhase 2

Active, not recruiting

PanuveitisPreclinical

Unknown

PyodermaPhase 3

Active, not recruiting

Anal FistulaApproved

Active, not recruiting

ArthritisPreclinical

Unknown

Rheumatic DiseasePhase 2

Recruiting

Anterior UveitisPhase 3

Active, not recruiting

Psoriasis VulgarisPreclinical

Unknown

Showing 10 of 59 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Humira

CCelltrion

Approved

2 2

Spikevax

Moderna

Preclinical

21 3

Aldactone

Pfizer

Preclinical

1 4

Nitrostat

VViatris Specialty LLC

Preclinical

1 5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 6

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 8

Calcium

Eli Lilly

Preclinical

—9

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 10

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Fluorescence

NCT03938701

Post-ApprovalRecruiting

Trial

NCT03917303

Q4 2026

Post-ApprovalNot yet recruiting

Uveitis

NCT05105347

Post-ApprovalRecruiting

Efficacy

NCT05626348

Q1 2027

Post-ApprovalRecruiting

Crohn's Disease

NCT06180382

Q2 2027

Post-ApprovalRecruiting

Efficacy and Safety

NCT06498089

Clinical

Trials by Indication[1]

Rheumatoid Arthritis46 trials

A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00233571·796 enrolled

Prospective Study on Intensive Early Rheumatoid Arthritis Treatment

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 4·NCT00480272·251 enrolled

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Completed·UUnknown Sponsor·Phase 3·NCT02760407·1,648 enrolled

Show 43 more trials

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis

Completed·SSamsung Bioepis Co., Ltd.·Phase 2·NCT02565810·49 enrolled

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis

Completed· Novartis logo

Novartis·Phase 3·NCT02744755·353 enrolled

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

Completed· AbbVie logo

AbbVie·Phase 2·NCT01712178·100 enrolled

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

Completed· AbbVie logo

AbbVie··NCT02668640·55 enrolled

Quality of Life Study With Adalimumab in Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00234936·200 enrolled

Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE

Completed·NNHS Greater Glasgow and Clyde·N/A·NCT05090124·46 enrolled

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 4·NCT02092467·4,372 enrolled

Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT02092961·198 enrolled

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Recruiting·UUniversita di Verona·Phase 4·NCT06527534·30 enrolled

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Completed· Amgen logo

Amgen·Phase 3·NCT01970475·526 enrolled

Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

Completed· AbbVie logo

AbbVie·Phase 1·NCT00650156·24 enrolled

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Unknown status·GGeorgetown University·Phase 4·NCT01793519·290 enrolled

Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

Approved for marketing·AAbbott··NCT00650026

A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)

Withdrawn· Merck & Co. logo

Merck & Co.··NCT00724672

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Completed· AbbVie logo

AbbVie·Phase 4·NCT01185288·309 enrolled

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00448383·6,610 enrolled

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT02557100·80 enrolled

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)

Completed· AbbVie logo

AbbVie·Phase 3·NCT01185301·395 enrolled

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

Completed· AbbVie logo

AbbVie·Phase 4·NCT02198651·149 enrolled

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 2·NCT00235833·25 enrolled

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 2/3·NCT00647491·352 enrolled

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting·UUniversity of Nebraska·Phase 3·NCT03414502·400 enrolled

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy

Completed· Roche logo

Roche··NCT01592292·90 enrolled

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

Completed· Astellas logo

Astellas·Phase 4·NCT03737708·21 enrolled

Effects of Abatacept on Myocarditis in Rheumatoid Arthritis

Terminated·—·Phase 4·NCT03619876·11 enrolled

Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)

Completed·UUniversity Hospital, Tours·Phase 4·NCT01382160·69 enrolled

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission

Completed· AbbVie logo

AbbVie·Phase 4·NCT00808509·33 enrolled

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00690573·25 enrolled

Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00837434·63 enrolled

Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers

Completed·GGlostrup University Hospital, Copenhagen··NCT01029613·40 enrolled

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

Not yet recruiting·TTufts Medical Center··NCT06016517·18 enrolled

Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring

Recruiting·—·Phase 4·NCT04194827·267 enrolled

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Completed· Gilead logo

Gilead·Phase 3·NCT02889796·1,759 enrolled

Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00603993·88 enrolled

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

Terminated·AAbbott·Phase 4·NCT00233558·160 enrolled

RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis

Terminated·TTcLand Expression S.A.··NCT03016260·250 enrolled

Predictors of the Response to Adalimumab in Rheumatoid Arthritis

Completed·UUniversity Hospital, Rouen·Phase 4·NCT00234234·200 enrolled

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00235872·309 enrolled

Post-marketing Observational Study in Subjects With Rheumatoid Arthritis

Completed·AAbbott··NCT00234884·3,435 enrolled

REstore Working Ability in RheumatoiD Arthritis

Unknown status·TThe Rheumatological Center of Helsinki·Phase 4·NCT01405326·160 enrolled

Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 4·NCT00649922·226 enrolled

Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis

Approved for marketing·AAbbott··NCT00649545

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 2·NCT01225393·211 enrolled

Psoriasis19 trials

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAlvotech Swiss AG·Phase 3·NCT04453137·567 enrolled

The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis

Unknown status·MMedical University of Vienna·Phase 4·NCT01088165·66 enrolled

Immunoclassification of Psoriasis: a Strategy for Precision Medicine

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05503875·100 enrolled

Show 16 more trials

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT05073315·425 enrolled

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAbbott·Phase 3·NCT00235820·271 enrolled

MAP Study: Methotrexate and Adalimumab in Psoriasis

Completed·JJeffrey J Crowley MD·Phase 2/3·NCT03217734·56 enrolled

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

Completed·UUniversity Hospitals Cleveland Medical Center··NCT02330380·26 enrolled

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

Completed·AAbbott·Phase 4·NCT00735787·81 enrolled

Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Completed·AAlvotech Swiss AG·Phase 3·NCT03849404·413 enrolled

Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAbbott·Phase 2·NCT00645905·148 enrolled

Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis

Completed·IInnovaderm Research Inc.·Phase 4·NCT00940862·30 enrolled

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02207231·837 enrolled

Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

Completed·JJochen Schmitt.··NCT01812954·1 enrolled

Effect of Adalimumab Therapy on Psoriasis Patient

Unknown status·SSohag University·N/A·NCT05889338·140 enrolled

Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

Completed·IInnovaderm Research Inc.·Phase 4·NCT01722214·107 enrolled

The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis

Unknown status·SSinocelltech Ltd.·Phase 3·NCT03927352·330 enrolled

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAbbott·Phase 3·NCT00195676·1,469 enrolled

A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02016482·217 enrolled

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01483599·293 enrolled

Adalimumab17 trials

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

Completed· Pfizer logo

Pfizer·Phase 1·NCT02237729·362 enrolled

Switching From Adalimumab to Infliximab

Completed·UUniversity Hospital, Ghent··NCT01338740·21 enrolled

A Clinical Study With Adalimumab Biosimilar

Completed·LLaboratorios Richmond S.A.C.I.F.·Phase 1·NCT06291948·150 enrolled

Show 14 more trials

ADALISKIAS: Adalimumab for Acute Disc Prolapse

Unknown status·KKuopio University Hospital·Phase 3·NCT01510548·90 enrolled

Adalimumab Microneedles in Healthy Volunteers

Completed·CCentre for Human Drug Research, Netherlands·Phase 1/2·NCT03607903·24 enrolled

Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806

Completed· AbbVie logo

AbbVie·Phase 3·NCT00686374·100 enrolled

Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)

Completed·AAlvotech Swiss AG·Phase 1·NCT03849313·390 enrolled

Yuflyma® (Adalimumab), Patient Experience After Switching

Unknown status·CCelltrion HealthCare France··NCT05427942·300 enrolled

Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05995691·179 enrolled

Doppler Evaluation in RA Patients After Adalimumab.

Completed·HHamed Rezaei·Phase 4·NCT01609205·60 enrolled

Abatacept Versus Adalimumab Head-to-Head

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00929864·869 enrolled

Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan

Completed·KKeio University·Phase 4·NCT03505008·300 enrolled

Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks

Unknown status·HHospital Universitario La Paz·Phase 3·NCT04404517·20 enrolled

ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)

Completed·UUniversity of Leeds·Phase 2·NCT04154852·22 enrolled

A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT01243671·20 enrolled

Therapeutic Monitoring of Infliximab and Adalimumab

Unknown status·IIRCCS Burlo Garofolo··NCT06033469·100 enrolled

Adalimumab Biosimilar in Clinical Practice

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT04808739·604 enrolled

Ankylosing Spondylitis11 trials

REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)

Unknown status·HHanyang University Seoul Hospital·Phase 4·NCT05164198·448 enrolled

The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients

Unknown status·QQilu Hospital of Shandong University·Phase 4·NCT05527444·100 enrolled

Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity

Completed·UUniversity Hospital, Montpellier·N/A·NCT01610947·398 enrolled

Show 8 more trials

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

Not yet recruiting·TThe Affiliated Hospital Of Guizhou Medical University·Phase 4·NCT06833112·10 enrolled

Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients

Completed· AbbVie logo

AbbVie··NCT02333383·201 enrolled

Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Unknown status·JJagiellonian University·Phase 4·NCT02132234·100 enrolled

Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study

Unknown status·—·Phase 4·NCT02489760·30 enrolled

Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients

Completed·UUniversidade Nova de Lisboa·Phase 4·NCT02492217·69 enrolled

A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis

Completed·AAbbott·Phase 3·NCT00667355·41 enrolled

Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

Completed·AAbbott·Phase 3·NCT01114880·344 enrolled

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

Withdrawn· Eli Lilly logo

Eli Lilly·Phase 3·NCT01870284

Uveitis10 trials

Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis

Active, not recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT06310837·128 enrolled

Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis

Unknown status·SSun Yat-sen University·Phase 2·NCT04588818·30 enrolled

Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis

Not yet recruiting·PPeking Union Medical College Hospital·Phase 4·NCT05105347·130 enrolled

Show 7 more trials

The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT05015335·50 enrolled

Treatment FOr Corticosteroid Dependent UveitiS

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06258915·120 enrolled

Adalimumab in JIA-associated Uveitis Stopping Trial

Completed·NNisha Acharya·Phase 4·NCT03816397·87 enrolled

Efficacy and Safety of Adalimumab in Patients With Active Uveitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01138657·239 enrolled

Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02929251·112 enrolled

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Completed·JJHSPH Center for Clinical Trials·Phase 3·NCT03828019·227 enrolled

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01148225·424 enrolled

47 more indications

Arthritis8 trials

Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)

Completed· AbbVie logo

AbbVie·Phase 3·NCT01064856·165 enrolled

A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

Terminated· AbbVie logo

AbbVie·Phase 4·NCT02897115·22 enrolled

Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01808118·673 enrolled

Show 5 more trials

Study of Adalimumab in Patients With Axial Spondyloarthritis

Completed· AbbVie logo

AbbVie·Phase 3·NCT00939003·192 enrolled

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Recruiting·TTom Appleton·Phase 2·NCT06037811·30 enrolled

Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis

Unknown status·UUniversity of Helsinki·Phase 4·NCT02634541·60 enrolled

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT02696785·341 enrolled

Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis

Completed·RRigshospitalet, Denmark·Phase 4·NCT01029847·49 enrolled

Psoriatic Arthritis8 trials

A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)

Completed·AAbbott·Phase 3·NCT00427362·127 enrolled

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

Terminated· Gilead logo

Gilead·Phase 3·NCT04115748·67 enrolled

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Completed·MMoonLake Immunotherapeutics AG·Phase 2·NCT05640245·207 enrolled

Show 5 more trials

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Completed·AAbbott·Phase 2·NCT00646386·315 enrolled

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Completed· AbbVie logo

AbbVie·Phase 3·NCT03104400·1,705 enrolled

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Completed·AAbbott·Phase 3·NCT00646178·102 enrolled

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01695239·417 enrolled

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

Completed· Novartis logo

Novartis·Phase 3·NCT02745080·853 enrolled

Crohn's Disease7 trials

Remission in Subjects With Crohn's Disease, Open Label Extension

Completed·AAbbott·Phase 3·NCT01070303·177 enrolled

Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115

Completed· AbbVie logo

AbbVie·Phase 3·NCT02185014·252 enrolled

Reduce Risk for Crohn's Disease Patients

Completed·PPIBD-Net·Phase 4·NCT02852694·192 enrolled

Show 4 more trials

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Completed·AAbbott·Phase 3·NCT00077779·854 enrolled

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

Completed·AAbbott·Phase 3·NCT00348283·135 enrolled

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04655807

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

Recruiting·—·Phase 4·NCT06180382·220 enrolled

Inflammatory Bowel Disease5 trials

Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease

Not yet recruiting·UUniversity Medical Center Groningen·Phase 1/2·NCT07258641·30 enrolled

Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease

Recruiting·UUniversity Medical Center Groningen·Phase 1/2·NCT06117423·21 enrolled

Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

Completed·RRehab Werida·N/A·NCT05291039·56 enrolled

Show 2 more trials

Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)

Completed· AbbVie logo

AbbVie··NCT02750800·427 enrolled

Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease

Withdrawn·UUniversity of Alberta·Phase 4·NCT00972218

Efficacy and Safety5 trials

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

Completed· Pfizer logo

Pfizer·Phase 4·NCT02187055·1,152 enrolled

The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

Not yet recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT07013838·50 enrolled

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

Approved for marketing·AAbbott··NCT00650390

Show 2 more trials

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT06498089·124 enrolled

Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate

Unknown status·KKeio University·Phase 4·NCT01270035·40 enrolled

Moderate to Severe Crohn's Disease5 trials

Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

Completed· AbbVie logo

AbbVie·Phase 2·NCT02015793·30 enrolled

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT02499783·205 enrolled

Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT01235689·252 enrolled

Show 2 more trials

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

Completed·AAbbott·Phase 3·NCT00427921·304 enrolled

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

Completed·AAbbott·Phase 3·NCT00409682·192 enrolled

Immunogenicity4 trials

Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

Completed·TTurgut İlaçları A.Ş.·Phase 1·NCT04439929·168 enrolled

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.

Completed· GSK logo

GSK·Phase 1·NCT01899755·45 enrolled

A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects

Recruiting·BBiocad·Phase 1·NCT07181694·444 enrolled

Show 1 more trial

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Unknown status·MMabscale, LLC·Phase 3·NCT06005532·494 enrolled

Hidradenitis Suppurativa4 trials

Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa

Completed· AbbVie logo

AbbVie·Phase 3·NCT01635764·508 enrolled

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Completed·AAbbott·Phase 2·NCT00918255·154 enrolled

A Study of LAD191 in Adults With Hidradenitis Suppurativa

Not yet recruiting·AAlmirall, S.A.·Phase 2·NCT07151937·200 enrolled

Show 1 more trial

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

Completed· AbbVie logo

AbbVie·Phase 4·NCT02808975·206 enrolled

Tics3 trials

Pharmacokinetics and Safety in Healthy Volunteers

Completed·SSinocelltech Ltd.·Phase 1·NCT03917628·146 enrolled

Pharmacokinetics and Safety in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02045979·327 enrolled

Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01505491·193 enrolled

Ulcerative Colitis3 trials

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

Completed·AAbbott·Phase 3·NCT00408629·518 enrolled

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT06257875·156 enrolled

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Completed· Roche logo

Roche·Phase 3·NCT02163759·358 enrolled

Bone Resorption2 trials

Bone Resorption, Osteoclastogenesis and Adalimumab

Completed·UUniversité de Sherbrooke·N/A·NCT00814866·28 enrolled

Bone Resorption, Osteoclastogenesis and Adalimumab

Unknown status·UUniversité de Sherbrooke·Phase 4·NCT02035800·120 enrolled

Treatment2 trials

Treatments Against RA and Effect on FDG-PET/CT

Completed·—·Phase 4·NCT02374021·159 enrolled

Treatment Tapering in JIA With Inactive Disease

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02840175·62 enrolled

Juvenile Idiopathic Arthritis2 trials

Juvenile Idiopathic Arthritis (JIA) Registry

Completed· AbbVie logo

AbbVie··NCT00783510·849 enrolled

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04527380·101 enrolled

Osteoarthritis2 trials

Adalimumab for Inflammatory Osteoarthritis

Completed·UUniversity of Alberta·Phase 1/2·NCT00686439·20 enrolled

A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis

Completed·SStanford University·Phase 2·NCT00185562·12 enrolled

Anal fistula2 trials

Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's

Completed·FFoundation for Liver Research·Phase 3·NCT00736983·76 enrolled

Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas

Completed·VVanderbilt University Medical Center·Phase 4·NCT00517296·21 enrolled

Crohn's Disease (CD)2 trials

Triple Combination Therapy in High Risk Crohn's Disease (CD)

Completed· Takeda logo

Takeda·Phase 4·NCT02764762·55 enrolled

Adalimumab for the Management of Post-operative Crohn's Disease (CD)

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 3·NCT01629628·100 enrolled

Takayasu arteritis2 trials

A Pilot Study in Severe Patients With Takayasu Arteritis.

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT04300686·40 enrolled

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

Recruiting·MMarmara University·N/A·NCT07491913·40 enrolled

MPA1 trial

Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers

Completed·AAlvotech Swiss AG·Phase 1·NCT03579823·24 enrolled

Fluorescence1 trial

Fluorescence Imaging of IBD and RA Using Adalimumab-800CW

Recruiting·UUniversity Medical Center Groningen·Phase 2·NCT03938701·36 enrolled

Dendritic Cell1 trial

Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy

Unknown status·UUniversity of Padova·Phase 4·NCT01237262·20 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept

Completed·IInnovaderm Research Inc.·Phase 3·NCT00927069·85 enrolled

Adult Subject1 trial

Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects

Completed·SSynermore Biologics Co., Ltd.·Phase 1·NCT03254810·94 enrolled

Real-world Study1 trial

A Real-world Study of Imraldi® Use

Completed· Biogen logo

Biogen··NCT04089514·1,000 enrolled

Systemic Therapy1 trial

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

Completed·AAbbott·Phase 3·NCT00566722·152 enrolled

Relapsing Polychondritis1 trial

An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Recruiting·UUniversity of Pennsylvania·Phase 2·NCT06941376·20 enrolled

Joint Disease1 trial

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

Completed·JJonathan Graf·Phase 4·NCT01893996·63 enrolled

Obstructive Sleep Apnea1 trial

Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea

Completed·IInnovaderm Research Inc.·Phase 4·NCT01181570·20 enrolled

Trial1 trial

Control Crohn Safe Trial

Recruiting·MMaastricht University Medical Center·Phase 4·NCT03917303·158 enrolled

Maintenance Therapy1 trial

Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)

Withdrawn·PPeter Higgins·Phase 3·NCT01674413

Choroidal Neovascularization1 trial

Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study

Unknown status·RRafic Hariri University Hospital·Phase 1·NCT00855608·15 enrolled

Pyoderma Gangrenosum1 trial

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

Completed· AbbVie logo

AbbVie·Phase 3·NCT03311464·22 enrolled

Effectiveness1 trial

Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice

Completed· AbbVie logo

AbbVie··NCT01736189·346 enrolled

Osteomyelitis1 trial

CHronic Nonbacterial Osteomyelitis International Registry

Recruiting·SSeattle Children's Hospital··NCT04725422·2,000 enrolled

Folliculitis1 trial

Biologics in Folliculitis Decalvans : an Adaptative Trial Research

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07268534·120 enrolled

Hermansky-Pudlak syndrome1 trial

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00514982

Dupuytren's Disease1 trial

Repurposing Anti-TNF for Treating Dupuytren's Disease

Completed·UUniversity of Oxford·Phase 2·NCT03180957·140 enrolled

Melanoma1 trial

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Completed· Roche logo

Roche·Phase 1·NCT04551352·20 enrolled

Sarcoidosis1 trial

Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis

Withdrawn·WWake Forest University·Phase 2·NCT00690911

Spondylarthropathies1 trial

TNFalfa Blocking Treatment of Spondylarthropathies

Completed·HHvidovre University Hospital·Phase 4·NCT00133315·50 enrolled

Pouchitis1 trial

Adalimumab in the Treatment of Chronic Pouchitis

Completed·OOdense University Hospital·Phase 3·NCT01670240·13 enrolled

Thyroid Cancer1 trial

A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers

Withdrawn·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT02516774

Methotrexate1 trial

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

Terminated· Sanofi logo

Sanofi·Phase 3·NCT01764997·776 enrolled

Age1 trial

Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects

Completed·—·Phase 1·NCT02252809·51 enrolled

Giant Cell Arteritis1 trial

HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00305539·69 enrolled

Efficacy1 trial

The Clinical Efficacy of Immunomodulators in RA Patients

Recruiting·QQilu Hospital of Shandong University·Phase 4·NCT05626348·400 enrolled

Cohort Study1 trial

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

Completed· Biogen logo

Biogen··NCT03662919·2,274 enrolled

Unspecified2 trials

Long Term Open Label Continuation Study

Completed·AAbbott·Phase 3·NCT00195650·846 enrolled

D2E7-Early AS

Unknown status·—·Phase 2/3·NCT00235105·46 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 31, 2002

Humira

BLA 125057

Dec 31, 2002

HUMIRA

BLA BLA125057

Oct 30, 2018

ADALIMUMAB

BLA BLA761071

Jul 23, 2019

HADLIMA

BLA BLA761059

May 23, 2023

ADALIMUMAB

BLA BLA761219

Sources

References

[1]
ClinicalTrials.gov — 412 trial records for Adalimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Humira drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Adalimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Adalimumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761219). U.S. Food & Drug Administration.
[6]
PubMed — 10 publications indexed for Adalimumab. U.S. National Library of Medicine.
[7]
SEC EDGAR — Celltrion company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: TNF-Alpha Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: CCelltrion

Key Publications[6]

Angiocrine factors in tumor microenvironment: bidirectional crosstalk, mechanistic insights, and therapeutic strategies.

J Transl MedJul 7, 2026DOI: 10.1186/s12967-026-08547-7

Sex differences in sleep architecture and nocturnal oxygenation across obstructive sleep apnea severity: an observational hospital-based study.

Biol Sex DifferJul 7, 2026DOI: 10.1186/s13293-026-00951-4

Troponin T clearance via continuous renal replacement therapies in the ICU.

J Intensive CareJul 7, 2026DOI: 10.1186/s40560-026-00900-8

Shared and Distinct Clinical Features in Treatment-Seeking Adults With Avoidant/Restrictive Food Intake Disorder or Anorexia Nervosa Subtypes.

Int J Eat DisordJul 6, 2026DOI: 10.1002/eat.70167

MRI-enhanced online adaptive radiotherapy by virtual integration of a standalone MRI simulator and CBCT-based treatment delivery.

Radiat OncolJul 6, 2026DOI: 10.1186/s13014-026-02887-w

KLF5-driven TAZ-FASN signaling reprograms fatty acid metabolism to support Treg differentiation in lung cancer.

J Transl MedJul 6, 2026DOI: 10.1186/s12967-026-08557-5

Barriers and enablers to implementing health education for HIV virologic suppression among adult people living with HIV-HBV coinfection in Northwest Ethiopia: a consolidated framework for implementation research guided qualitative study.

AIDS Res TherJul 6, 2026DOI: 10.1186/s12981-026-00922-0

Genomic Medicine Sweden: Advancing precision medicine at the national level.

J Intern MedJul 6, 2026DOI: 10.1111/joim.70129

Role of microRNAs in cisplatin response of cancer stem cells.

Stem Cell Res TherJul 6, 2026DOI: 10.1186/s13287-026-05161-8

Mortality effect of albumin fluid resuscitation in adults with septic shock: a systematic review and dual frequentist-bayesian meta-analysis of randomised trials.

Crit CareJul 6, 2026DOI: 10.1186/s13054-026-06172-w

Humira

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Rheumatoid Arthritis46 trials

Psoriasis19 trials

Adalimumab17 trials

Ankylosing Spondylitis11 trials

Uveitis10 trials

Arthritis8 trials

Psoriatic Arthritis8 trials

Crohn's Disease7 trials

Inflammatory Bowel Disease5 trials

Efficacy and Safety5 trials

Moderate to Severe Crohn's Disease5 trials

Immunogenicity4 trials

Hidradenitis Suppurativa4 trials

Tics3 trials

Ulcerative Colitis3 trials

Bone Resorption2 trials

Treatment2 trials

Juvenile Idiopathic Arthritis2 trials

Osteoarthritis2 trials

Anal fistula2 trials

Crohn's Disease (CD)2 trials

Takayasu arteritis2 trials

MPA1 trial

Fluorescence1 trial

Dendritic Cell1 trial

Safety and Efficacy1 trial

Adult Subject1 trial

Real-world Study1 trial

Systemic Therapy1 trial

Relapsing Polychondritis1 trial

Joint Disease1 trial

Obstructive Sleep Apnea1 trial

Trial1 trial

Maintenance Therapy1 trial

Choroidal Neovascularization1 trial

Pyoderma Gangrenosum1 trial

Effectiveness1 trial

Osteomyelitis1 trial

Folliculitis1 trial

Hermansky-Pudlak syndrome1 trial

Dupuytren's Disease1 trial

Melanoma1 trial

Sarcoidosis1 trial

Spondylarthropathies1 trial

Pouchitis1 trial

Thyroid Cancer1 trial

Methotrexate1 trial

Age1 trial

Giant Cell Arteritis1 trial

Efficacy1 trial

Cohort Study1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Key Publications[6]

Related News